MapLight Therapeutics (MPLT) Total Current Liabilities (2024 - 2025)

MapLight Therapeutics' (MPLT) quarterly Total Current Liabilities came in at $16.2 million in Q4 2025, up 1.94% year-on-year from $15.9 million in Q4 2024, and down 12.57% quarter-over-quarter from $18.6 million in Q3 2025.

MapLight Therapeutics (MPLT) Total Current Liabilities (2024 - 2025) Analysis & Trends

MapLight Therapeutics has disclosed Total Current Liabilities across 2 years of filings, most recently posting $16.2 million for Q4 2025.

  • Total Current Liabilities for Q4 2025 came in at $16.2 million, up 1.94% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.2 million (up 1.94% YoY), and the FY2025 annual result was $16.2 million, up 1.94% from the prior year.
  • Total Current Liabilities came in at $16.2 million for Q4 2025 at MapLight Therapeutics, down from $18.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $18.6 million in Q3 2025 to a low of $15.9 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 1.70 Mn
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 16.35 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 636.40 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 13.42 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 3.88 Bn
9 Abivax 91.96 Bn 91.96 Bn - 72.86 Mn
10 MapLight Therapeutics 248.88 Mn 248.88 Mn - 16.23 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 16.23 Mn
Sep 30, 2025 18.56 Mn
Dec 31, 2024 15.92 Mn